Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
| dsm-firmenich Switzerland AG | INDUSTRY |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NIH |
Not provided
Not provided
Not provided
Not provided
Purpose: Determine the effects of maternal docosahexaenoic acid (DHA) supplementation during pregnancy on levels of DHA, synaptamide (novel anti-inflammatory metabolite), and inflammatory biomarkers during pregnancy and at delivery
Research Design: Double blind randomized placebo-controlled study of maternal DHA supplementation during pregnancy.
Methodology /Technical Approach: Investigators plan to enroll 100 pregnant women with a high risk pregnancy related to (1) a pre-pregnancy Body Mass Index (BMI) of ≥30.0 kg/m2 and/or (2) a history of prior preterm delivery at ≤35+6 weeks gestation. Women will be enrolled between the 8th and 14th week of pregnancy and randomized to receive a once daily DHA supplement (DSM Nutritional Products, Columbia Maryland, DHA capsule 441mg/cap) or a placebo (DSM Nutritional Products, Columbia Maryland, Corn Oil/Soybean oil 50/50 mix) for the duration of the pregnancy. DHA is an omega-3 long chain polyunsaturated fatty acid (LCPUFA) and placebo composed of omega-6 LCPUFA's. Investigators will measure maternal levels of plasma DHA, Synaptamide and inflammatory biomarkers at enrollment, at 26-30 weeks of pregnancy, and from cord blood at delivery. Sociodemographic and clinical characteristics will be collected for each mother from pregnancy onset until discharge following delivery. The infant health record and parental report will be reviewed to record clinical data from birth to 12 months corrected age for short term health outcomes potentially related to inflammation-related morbidities, including growth and development, acute infection requiring hospital admission, and any allergic disorder. All plasma samples will be processed at Dr. Kim's NIAAA/NIH laboratories using high-performance liquid chromatography with tandem mass spectrometry
All pregnant women meeting the inclusion/exclusion criteria will be identified at the time of their regular OB appointments between the 8th and the 14th week of pregnancy (+/- 3 days) Research team members will approach potential subjects to explain the study and obtain consent for their participation Patients who give their consent for enrollment will be asked to complete a dietary survey at the time of enrollment Patients will be given a paper script for study drug to be taken to the Walter Reed Military Medical Center pharmacy to obtain study drug The Investigational Pharmacy will randomize the patients in double blinded fashion to the intervention group or placebo group.
Patients in the intervention group will recieve a ~1000mg capsule containing ~400mg of DHA. This is not standard of care and is being done for research purposes only Patients in the Placebo group will recieve a ~1000mg capusle containing no DHA and filled with 50:50 mix of corn and soybean oils. This oil is ubiquitous in the american diet and only a very small amount of additional oil will be ingested for study purposes. Giving pregnant women this oil is not standard of care and is being done for research purposes only The placebo and intervention drugs will be packaged in the same capsule membrane and will be indistinguishable by color, shape, or taste.
Patients will be instructed to take 1 capule PO daily until their child is delivered Patients will be issued a 3 month supply of study drug at enrollment and will get refills from the investigational pharmacy
≤5ml of whole blood will be obtained from each subject at enrollment and at 26-30 weeks gestation (+/- 3 days), as part of a routine blood sampling. It is standard of care to collect blood at this point in pregnancy for lab evaluation. The additional tube of blood collected for this study is for research purposes only and not part of the standard of care. This sample will be centrifuged, and the separated plasma will be labeled and frozen at -80° C pending transport to Dr. Kim's lab at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for bulk analyses.
At delivery, ≤5ml of umbilical cord blood will be obtained from an umbilical artery and from the umbilical vein. These samples will be processed and stored in a similar fashion as the earlier samples. Cord blood is a medical waste product, and collection will therefore have no adverse effect for either mother or newborn. It is standard of care to collect cord blood by OB request for lab evaluation. Collecting additional cord blood for this study anaylsis is for research purposes only All enrollees will complete a dietary survey upon enrollment at 8-14 weeks (+/- 3 days), at 26-30th week of pregnancy (+/- 3 days), and during the delivery admission. This survey will also include the subject's self-report on compliance with taking the study supplement All plasma samples collected will be processed at Dr. Kim's National Institute on Alcohol Abuse and Alcoholism/ National Insititute of Health (NIAAA/NIH) laboratories The Cytokine Assays for IL-6, Il-10, TNF- alpha will be run in Dr Kim's lab using Ensyme Linked Immunosorbent Assay (ELISA) testing The DHA and Synaptamide levels will be analyzed in Dr. Kim's lab using High performance liquid chromatrography with tandem mass spectrometry All babies from multiple birth pregnancies will be enrolled in this study The offspring of enrolled women will be followed through 12 months corrected age to assess the longer term outcomes of study intervention Information will be collected from the maternal medical record at time of enrollment, infant delivery and postpartum discharge.
Information will be collected from the infant medical record at time of birth discharge, and 12 months corrected age.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DHA supplement | Active Comparator | Patients in the intervention group will recieve a ~1000mg capsule containing ~400mg of DHA. This is not standard of care and is being done for research purposes only. Patients will take this capsule once daily begining between 8-14 weeks of pregnancy until delivery of their infant. |
|
| corn oil: Soybean oil placebo | Placebo Comparator | Patients in the Placebo group will recieve a ~1000mg capusle containing no DHA and filled with 50:50 mix of corn and soybean oils. This oil is ubiquitous in the american diet and only a very small amount of additional oil will be ingested for study purposes. Giving pregnant women this oil is not standard of care and is being done for research purposes only. Patients will continue taking this placebo from enrollment at 8-14 weeks of pregnancy until time of delivery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DHA supplement | Dietary Supplement | Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through delivery of their infant |
| Measure | Description | Time Frame |
|---|---|---|
| Measure DHA | Measurement of maternal plasma DHA using tandem mass spec | Sample obtained between 8-14 weeks of pregnancy |
| Measure DHA | Measurement of maternal plasma DHA using tandem mass spec | Sample obtained between 26-30 weeks of pregnancy |
| Measure DHA | Measurement of fetal plasma DHA using tandem mass spec | Sample obtained from cord blood at time of infant delivery |
| Measure synaptamide | Measurement of maternal plasma synaptamide using tandem mass spec | Sample obtained between 8-14 weeks of pregnancy |
| Measure synaptamide | Measurement of maternal plasma synaptamide using tandem mass spec | Sample obtained between 26-30 weeks of pregnancy |
| Measure synaptamide | Measurement of fetal plasma synaptamide using tandem mass spec | Sample obtained from cord blood at time of infant delivery |
| Measure inflammatory biomarkers | Measurement of plasma cytokine levels using ELISA human cytokine panel | Sample obtained between 8-14 weeks of pregnancy |
| Measure inflammatory biomarkers |
| Measure | Description | Time Frame |
|---|---|---|
| Maternal Gestational weight gain at end of pregnancy in placebo vs. DHA supplement groups | Compare maternal gestational weight gain at the end of pregnancy between intervention and placebo groups | At time of infant delivery |
| Infant delivery method |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Enrolling only pregnant women and their offspring
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Peter F Knickerbocker, DO | Contact | 215-298-2476 | peteknickerbocker@gmail.com | |
| Carl Hunt, MD | Contact | 3017675514 | carl.hunt@usuhs.edu |
| Name | Affiliation | Role |
|---|---|---|
| Peter F Knickerbocker, DO | Walter Reed National Miltary Medical Center | Principal Investigator |
| Kim Hee-Yong, PhD | NIH/ NIAAA | Study Director |
| Carl Hunt, MD |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Walter Reed National Miltiary medical center | Recruiting | Bethesda | Maryland | 20889 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22585914 | Background | Valentine CJ. Maternal dietary DHA supplementation to improve inflammatory outcomes in the preterm infant. Adv Nutr. 2012 May 1;3(3):370-6. doi: 10.3945/an.111.001248. | |
| 21658712 | Background | Martin CR, Dasilva DA, Cluette-Brown JE, Dimonda C, Hamill A, Bhutta AQ, Coronel E, Wilschanski M, Stephens AJ, Driscoll DF, Bistrian BR, Ware JH, Zaman MM, Freedman SD. Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities. J Pediatr. 2011 Nov;159(5):743-749.e1-2. doi: 10.1016/j.jpeds.2011.04.039. Epub 2011 Jun 12. |
Not provided
Not provided
All study data will be coded and master key will only be available to study personnel at Walter Reed National Military Medical Center. No decoded study data will be provided to the NIH/NIAAA
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007249 | Inflammation |
| D047928 | Premature Birth |
| D050177 | Overweight |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007752 | Obstetric Labor, Premature |
| D007744 | Obstetric Labor Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D004281 | Docosahexaenoic Acids |
| ID | Term |
|---|---|
| D015525 | Fatty Acids, Omega-3 |
| D004042 | Dietary Fats, Unsaturated |
| D004041 | Dietary Fats |
| D005223 | Fats |
Not provided
Not provided
Double Blinded, Randomized, Placebo controlled
Not provided
Not provided
Double blinded, randomized, placebo controlled
|
| Corn Oil: Soybean Oil | Dietary Supplement | Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through |
|
Measurement of plasma cytokine levels using ELISA human cytokine panel
| Sample obtained between 26-30 weeks of pregnancy |
| Measure inflammatory biomarkers | Measurement of plasma cytokine levels using ELISA human cytokine panel | Sample obtained from cord blood at time of infant delivery |
Compare delivery method used to delivery infant between intervention and placebo groups
| At time of infant delivery |
| Delivery complications | Compare any documented delivery complications between intervention and placebo groups | at time of infant delivery |
| Maternal death | Number of maternal deaths in intervention group vs placebo group | From enrollment in study at 8-14 weeks of pregnancy until 6 months after infant delivery |
| Pre-eclampsia | Presence or absence of pre-eclampsia in intervention vs placebo groups | From enrollment in study at 8-14 weeks of pregnancy until 42 weeks of pregnancy or day of infant delivery, whichever happens first |
| chorioamionitis | Presence or absence of chorioamionitis in intervention vs placebo groups | From enrollment in study at 8-14 weeks of pregnancy until 42 weeks of pregnancy or day of infant delivery, whichever happens first |
| Gestational Diabetes Melitus | Presence or absence of Gestational Diabetes Mellitus in intervention vs placebo groups | From enrollment in study at 8-14 weeks of pregnancy until 42 weeks of pregnancy or day of infant delivery, whichever happens first |
| non-gestational Diabetes mellitus | Presence or absence of non-Gestational Diabetes Mellitus in intervention vs placebo groups | From enrollment in study at 8-14 weeks of pregnancy until 42 weeks of pregnancy or day of infant delivery, whichever happens first |
| Preterm Premature Rupture of Membranes | Presence or absence of Preterm Premature Rupture of Membranes in intervention vs placebo groups | From enrollment in study at 8-14 weeks of pregnancy until 42 weeks of pregnancy or day of infant delivery, whichever happens first |
| going past due dates | Presence or absence of going past due dates in intervention vs placebo groups | during last month of pregnancy |
| Placental pathology | Any placental pathology documented on maternal delivery summary in intervention vs. placebo groups | at time of delivery |
| Head circumference at birth | Measurement of head circumference at birth in placebo vs. Intervention | At time of infant birth |
| Length at birth | Measurement of length at birth in placebo vs. Intervention | At time of infant birth |
| weight at birth | Measurement of weight at birth in placebo vs. Intervention | At time of infant birth |
| Gestational age at birth | Gestational age at infant birth in both placebo and intervention groups | At time of infant birth |
| APGAR score at 1 min | APGAR score assessed for infants in both placebo and intervention groups | At time of infant birth |
| APGAR score at 5 min | APGAR score assessed for infants in both placebo and intervention groups | At time of infant birth |
| Resuscitation beyond warm/dry stimulate at birth | Presence or absence of any resuscitation beyond warm, dry and stimulate at infant birth | At time of infant birth |
| Presence or absence or requirement for respiratory assistance within the first 24 hours after birth | Presence or absence of any respiratory support outside of the delivery room in first 24 hours of birth placebo vs intervention groups | From NICU admission to 24 hours after birth |
| Days of antibiotic exposure during birth hospitalization | Number of 24hr periods in which infant was exposed to antibiotics during birth hospitalization | During birth admission up to 8 months of chronologic age or discharge from hospital whichever happens sooner |
| NICU admission | Presence or absence of NICU admission in placebo vs intervention groups | Within the first 5 days of infant's life |
| Duration of birth admission | Number of 24hr periods patient was present in hospital during birth admission | Birth through 12 months of age or infant discharge, whichever occurs sooner |
| Requirement for phototherapy during birth admission | Presence or absence of phototherapy during birth admission in placebo vs intervention groups | Birth through 14 days of infant life |
| Culture proven sepsis | Presence or absence of culture proven sepsis during birth admission in placebo vs intervention groups | From birth through 12 months or until infant discharge whichever occurs sooner |
| Infant Death | Number of infants that died during birth hospitalization in both the placebo and intervention groups | From birth through 12 months or until infant discharge whichever occurs sooner |
| Weight at infant hospital discharge | Weight at infant hospital discharge in placebo vs intervention group | At time of infant's first discharge from hospital or at 12 months corrected, whichever comes first |
| head circumference at infant hospital discharge | head circumference at infant hospital discharge in placebo vs intervention group | At time of infant's first discharge from hospital or at 12 months corrected, whichever comes first |
| Length at infant hospital discharge | Length at infant hospital discharge in placebo vs intervention group | At time of infant's first discharge from hospital or at 12 months corrected, whichever comes first |
| Feeding plan at infant discharge | Feeding plan documented as exclusive breastfeeding, formula and breastfeeding or exclusive formula feeding | At 12 months chronological if still admitted or at infant discharge, whichever occurs sooner |
| Infant diagnosis in medical record | Compare infant diagnosis recorded in medical record in placebo vs intervention group | at 12 months corrected |
| infant weight at 6 months corrected age | Weight at 6 months corrected age documented in medical record in placebo vs intervention group | at 6 months corrected |
| infant weight at 12 months corrected age | Weight at 12 months corrected age documented in medical record in placebo vs intervention group | at 12 months corrected |
| head circumferene weight at 6 months corrected age | head circumferene at 6 months corrected age documented in medical record in placebo vs intervention group | at 6 months corrected |
| head circumference weight at 12 months corrected age | head circumference at 12 months corrected age documented in medical record in placebo vs intervention group | at 12 months corrected |
| Length weight at 6 months corrected age | Length at 6 months corrected age documented in medical record in placebo vs intervention group | at 6 months corrected |
| Length weight at 12 months corrected age | Length at 12 months corrected age documented in medical record in placebo vs intervention group | at 12 months corrected |
| Number of outpatient visits for infant during first 12 months corrected | Number of outpatient visits recorded during first 12 months corrected in placebo vs. intervention groups | birth through12 months corrected |
| Failure to thrive in for infant | Presence or absence of diagnosis "failure to thrive" in medical record through first 12 months corrected in placebo vs intervention | birth through 12 months corrected |
| number of inpatient days for infant through 12 months corrected | number of inpatient days for infant through 12 months corrected in intervention vs placebo | birth through 12 months corrected |
| Indication of infant developmental delay in medical record from birth through 12 months corrected | Presence or absence of any indication of developmental delay recorded by physician in the medical record through 12 months corrected in intervention vs placebo groups | birth through 12 months corrected |
| Number of antibiotic prescriptions for infant through first 12 months corrected | Number of antibiotic prescriptions for infant through first 12 months corrected in intervention vs placebo | birth through 12 months corrected |
| Documented infant feeding plan through first year | Documented infant feeding plan through first year. Exclusive breastfeeding, formula and breastfeeding or exclusive formula | birth through 12 months corrected |
| Uniformed Services University of the Health Sciences |
| Study Chair |
| 23044165 | Background | Ma L, Li N, Liu X, Shaw L, Li Calzi S, Grant MB, Neu J. Arginyl-glutamine dipeptide or docosahexaenoic acid attenuate hyperoxia-induced lung injury in neonatal mice. Nutrition. 2012 Nov-Dec;28(11-12):1186-91. doi: 10.1016/j.nut.2012.04.001. |
| 23994220 | Background | Hofer N, Kothari R, Morris N, Muller W, Resch B. The fetal inflammatory response syndrome is a risk factor for morbidity in preterm neonates. Am J Obstet Gynecol. 2013 Dec;209(6):542.e1-542.e11. doi: 10.1016/j.ajog.2013.08.030. Epub 2013 Aug 29. |
| 11548181 | Background | De Dooy JJ, Mahieu LM, Van Bever HP. The role of inflammation in the development of chronic lung disease in neonates. Eur J Pediatr. 2001 Aug;160(8):457-63. doi: 10.1007/s004310100785. |
| 25269386 | Background | Cheng SB, Sharma S. Interleukin-10: a pleiotropic regulator in pregnancy. Am J Reprod Immunol. 2015 Jun;73(6):487-500. doi: 10.1111/aji.12329. Epub 2014 Oct 1. |
| 22959887 | Background | Kim HY, Spector AA. Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. Prostaglandins Leukot Essent Fatty Acids. 2013 Jan;88(1):121-5. doi: 10.1016/j.plefa.2012.08.002. Epub 2012 Sep 5. |
| 24780080 | Background | Meijerink J, Poland M, Balvers MG, Plastina P, Lute C, Dwarkasing J, van Norren K, Witkamp RF. Inhibition of COX-2-mediated eicosanoid production plays a major role in the anti-inflammatory effects of the endocannabinoid N-docosahexaenoylethanolamine (DHEA) in macrophages. Br J Pharmacol. 2015 Jan;172(1):24-37. doi: 10.1111/bph.12747. Epub 2014 Sep 23. |
| 20601112 | Background | Balvers MG, Verhoeckx KC, Plastina P, Wortelboer HM, Meijerink J, Witkamp RF. Docosahexaenoic acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl ethanolamines with anti-inflammatory properties. Biochim Biophys Acta. 2010 Oct;1801(10):1107-14. doi: 10.1016/j.bbalip.2010.06.006. Epub 2010 Jun 27. |
| 20959577 | Background | Makrides M, Gibson RA, McPhee AJ, Yelland L, Quinlivan J, Ryan P; DOMInO Investigative Team. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA. 2010 Oct 20;304(15):1675-83. doi: 10.1001/jama.2010.1507. |
| 17185423 | Background | Dunstan JA, Simmer K, Dixon G, Prescott SL. Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2008 Jan;93(1):F45-50. doi: 10.1136/adc.2006.099085. Epub 2006 Dec 21. |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D008055 |
| Lipids |
| D005231 | Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D005395 | Fish Oils |
| D009821 | Oils |